Registro completo de metadatos
| Campo DC | Valor | Lengua/Idioma |
|---|---|---|
| dc.creator | Negrotto, Soledad | - |
| dc.creator | Hu, Zhenbo | - |
| dc.creator | Alcazar, Oscar | - |
| dc.creator | Ng, Kwok Peng | - |
| dc.creator | Triozzi, Pierre | - |
| dc.creator | Lindner, Daniel | - |
| dc.creator | Rini, Brian | - |
| dc.creator | Saunthararajah, Yogen | - |
| dc.date | 2018-07-24T14:26:09Z | - |
| dc.date | 2018-07-24T14:26:09Z | - |
| dc.date | 2011-02 | - |
| dc.date | 2018-07-23T18:28:02Z | - |
| dc.date.accessioned | 2019-04-29T15:53:13Z | - |
| dc.date.available | 2019-04-29T15:53:13Z | - |
| dc.date.issued | 2018-07-24T14:26:09Z | - |
| dc.date.issued | 2018-07-24T14:26:09Z | - |
| dc.date.issued | 2011-02 | - |
| dc.date.issued | 2018-07-23T18:28:02Z | - |
| dc.identifier | Negrotto, Soledad; Hu, Zhenbo; Alcazar, Oscar; Ng, Kwok Peng; Triozzi, Pierre; et al.; Noncytotoxic differentiation treatment of renal cell cancer; American Association for Cancer Research; Cancer Research; 71; 4; 2-2011; 1431-1441 | - |
| dc.identifier | 0008-5472 | - |
| dc.identifier | http://hdl.handle.net/11336/52945 | - |
| dc.identifier | CONICET Digital | - |
| dc.identifier | CONICET | - |
| dc.identifier.uri | http://rodna.bn.gov.ar:8080/jspui/handle/bnmm/304655 | - |
| dc.description | Current drug therapy for metastatic renal cell cancer (RCC) results in temporary disease control but not cure, necessitating continued investigation into alternative mechanistic approaches. Drugs that inhibit chromatin-modifying enzymes involved in transcription repression (chromatin-relaxing drugs) could have a role, by inducing apoptosis and/or through differentiation pathways. At low doses, the cytosine analogue decitabine (DAC) can be used to deplete DNA methyl-transferase 1 (DNMT1), modify chromatin, and alter differentiation without causing apoptosis (cytotoxicity). Noncytotoxic regimens of DAC were evaluated for in vitro and in vivo efficacy against RCC cell lines, including a p53-mutated RCC cell line developed from a patient with treatment-refractory metastatic RCC. The cell division - permissive mechanism of action - absence of early apoptosis or DNA damage, increase in expression of HNF4α (hepatocyte nuclear factor 4a), a key driver associated with the mesenchymal to epithelial transition, decrease in mesenchymal marker expression, increase in epithelial marker expression, and late increase in cyclin-dependent kinase inhibitor CDKN1B (p27) protein - was consistent with differentiation-mediated cell-cycle exit. In vivo blood counts and animal weights were consistent with minimal toxicity of therapy. The distinctive mechanism of action of a dose and schedule of DAC designed for noncytotoxic depletion of DNMT1 suggests a potential role in treating RCC. ©2011 AACR. | - |
| dc.description | Fil: Negrotto, Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Cleveland Clinic; Estados Unidos | - |
| dc.description | Fil: Hu, Zhenbo. Cleveland Clinic; Estados Unidos | - |
| dc.description | Fil: Alcazar, Oscar. Cleveland Clinic; Estados Unidos | - |
| dc.description | Fil: Ng, Kwok Peng. Cleveland Clinic; Estados Unidos | - |
| dc.description | Fil: Triozzi, Pierre. Cleveland Clinic; Estados Unidos | - |
| dc.description | Fil: Lindner, Daniel. Cleveland Clinic; Estados Unidos | - |
| dc.description | Fil: Rini, Brian. Cleveland Clinic; Estados Unidos | - |
| dc.description | Fil: Saunthararajah, Yogen. Cleveland Clinic; Estados Unidos | - |
| dc.format | application/pdf | - |
| dc.format | application/pdf | - |
| dc.format | application/pdf | - |
| dc.language | eng | - |
| dc.publisher | American Association for Cancer Research | - |
| dc.relation | info:eu-repo/semantics/altIdentifier/doi/https://dx.doi.org/10.1158/0008-5472.CAN-10-2422 | - |
| dc.relation | info:eu-repo/semantics/altIdentifier/url/http://cancerres.aacrjournals.org/content/71/4/1431 | - |
| dc.rights | info:eu-repo/semantics/openAccess | - |
| dc.rights | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | - |
| dc.source | reponame:CONICET Digital (CONICET) | - |
| dc.source | instname:Consejo Nacional de Investigaciones Científicas y Técnicas | - |
| dc.source | instacron:CONICET | - |
| dc.subject | DECITABINE | - |
| dc.subject | DIFFERENTIATION | - |
| dc.subject | RENAL CARCINOMA | - |
| dc.subject | CANCER TREATMENT | - |
| dc.subject | Inmunología | - |
| dc.subject | Medicina Básica | - |
| dc.subject | CIENCIAS MÉDICAS Y DE LA SALUD | - |
| dc.title | Noncytotoxic differentiation treatment of renal cell cancer | - |
| dc.type | info:eu-repo/semantics/article | - |
| dc.type | info:eu-repo/semantics/publishedVersion | - |
| dc.type | info:ar-repo/semantics/articulo | - |
| Aparece en las colecciones: | CONICET | |
Ficheros en este ítem:
No hay ficheros asociados a este ítem.